GSK is also described as placing Engitix’s extracellular-matrix disease models into a broader, multi-target framework focused on liver biology. The agreement ties to Engitix’s disease-model approach designed to generate disease-relevant hypotheses and targets for upstream validation. The reporting emphasizes that Engitix will use ECM-based disease models and multi-omics to identify new opportunities, while GSK retains the option to license targets, assays, and other outputs for further R&D and commercialization planning. Financial terms are presented as near-term funding and milestone potential tied to each validated target. This cluster duplicates the same underlying event as the separate GSK/Engitix funding item, so the operational impact centers on expanding GSK’s fibrosis and hepatology target discovery resources via Engitix’s model platform.